Innovent Shares Promising Phase 1 Results of IBI3003 for Myeloma Patients #China #Suzhou #Multiple_Myeloma #Innovent #IBI3003
@newsen.bsky.social@newsen.bsky.social
@newsen.bsky.socialInnovent Shares Promising Phase 1 Results of IBI3003 for Myeloma Patients #China #Suzhou #Multiple_Myeloma #Innovent #IBI3003